Table 4.
Odds ratios (ORs) and 95% confidence intervals (CIs) of the clinical status and FSCN1 rs2966447 genotypic frequencies in patients with breast cancer.
| Variable | Luminal A | Luminal B | HER2 overexpression | TNBC | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AA N=76(%) | AT+TT N=28(%) | OR (95% CI) | AA N=84(%) | AT+TT N=33(%) | OR (95% CI) | AA N=46(%) | AT+TT N=12(%) | OR (95% CI) | AA N=34(%) | AT+TT N=8(%) | OR (95% CI) | |
| Clinical stage | ||||||||||||
| Stage I/II | 67 (88.2) | 20 (71.4) | 1.00 (reference) | 60 (71.4) | 26 (78.8) | 1.00 (reference) | 30 (65.2) | 8 (66.7) | 1.00 (reference) | 26 (89.7) | 6 (75.0) | 1.00 (reference) |
| Stage III/IV | 9 (11.8) | 8 (28.6) | 2.978 (1.016–8.728)* | 24 (28.6) | 7 (21.2) | 0.673 (0.258–1.757) | 16 (34.8) | 4 (33.3) | 0.938 (0.244–3.598) | 3 (10.3) | 2 (25.0) | 2.889 (0.392–21.289) |
| Tumor size | ||||||||||||
| ≦ T2 | 76 (100) | 27 (96.4) | 1.00 (reference) | 78 (92.9) | 33 (100) | 1.00 (reference) | 40 (87.0) | 11 (91.7) | 1.00 (reference) | 28 (96.6) | 7 (87.5) | 1.00 (reference) |
| >T2 | 0 (0) | 1 (3.6) | — | 6 (7.1) | 0 (0) | — | 6 (13.0) | 1 (8.3) | 0.606 (0.066–5.578) | 1 (3.4) | 1 (12.5) | 4.000 (0.222–72.183) |
| Lymph node status | ||||||||||||
| N0+N1 | 67 (88.2) | 20 (71.4) | 1.00 (reference) | 60 (71.4) | 26 (78.8) | 1.00 (reference) | 34 (73.9) | 9 (75.0) | 1.00 (reference) | 26 (89.7) | 6 (75.0) | 1.00 (reference) |
| N2+N3 | 9 (11.8) | 8 (28.6) | 2.978 (1.016–8.728)* | 24 (28.6) | 7 (21.2) | 0.673 (0.258–1.757) | 12 (26.1) | 3 (25.0) | 0.944 (0.219–4.079) | 3 (10.3) | 2 (25.0) | 2.889 (0.392–21.289) |
| Distant metastasis | ||||||||||||
| M0 | 75 (98.7) | 27 (96.4) | 1.00 (reference) | 82 (97.6) | 33 (100) | 1.00 (reference) | 42 (91.3) | 12 (100) | 1.00 (reference) | 27 (93.1) | 8 (100) | 1.00 (reference) |
| M1 | 1 (1.3) | 1 (3.6) | 2.778 (0.168–45.977) | 2 (2.4) | 0 (0) | — | 4 (8.7) | 0 (0) | — | 2 (6.9) | 0 (0) | — |
| Pathologic grade | ||||||||||||
| G1+G2 | 74 (97.4) | 25 (89.3) | 1.00 (reference) | 64 (71.4) | 18 (54.5) | 1.00 (reference) | 23 (50.0) | 2 (16.7) | 1.00 (reference) | 10 (34.5) | 3 (37.5) | 1.00 (reference) |
| G3 | 2 (2.6) | 3 (10.7) | 4.440 (0.701–28.118) | 24 (28.6) | 15 (45.5) | 2.667 (1.140–6.236)* | 23 (50.0) | 10 (83.3) | 5.000 (0.985–25.379) | 19 (65.5) | 5 (62.5) | 0.877 (0.173–4.447) |
The ORs with their 95% CIs were estimated by logistic regression analysis. *p < 0.05 was statistically significant. HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer. Pathological grade: G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated.